NASP Speciality Pharmacy Podcast

During this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Bethany Kalich, PharmD, CLS, a Cardiovascular Medical Director and Asset Lead for the US Medical Team. Tune in for a conversation on the critical role of pharmacists and healthcare agencies in addressing gender inequalities in cardiovascular health.Sheila Arquette, President & CEO of NASP, speaks with Bethany Kalich, PharmD, CLS

Episode 3 of the NASP Post Show! In this episode we talk with
Nicholas Ruiz - keycentrix
Richard Brook - Better Health Worldwide / NPRT
Russel Robbins - PurpleLab
Saumya Rawat - Pharmesol
David Bronstein - Specialty Pharmacy Continuum
Tim McLeroy - Noble International

Jennifer Donovan, Pharm D, is the vice president of clinical services at Shields Health Solutions. In thisrole, Jen leads the Clinical Services, Training and Outcomes teams. She’s responsible for ensuring Shieldsprovides best-in-class patient care that’s evidence-based and adheres to external requirements, workingcross functionally with various departments.Prior to Shields, Jen was the Associate Dean for the School of Pharmacy – Worcester/Manchester andProfessor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences in Worcester,MA. Jen earned a Doctor of Pharmacy degree from Massachusetts College of Pharmacy and HealthSciences and completed a pharmacy practice residency at UMass Memorial Medical Center.Jen lives in the New England area with her husband and two kids.
 

Episode 2 of the NASP Post Show! In this episode we talk with
 
Jonathan Levitt 
Jonathan Ogurchak - STACK Zeal Specialty
Julie Allen - Policy Advocacy NASP
Luis Rodriguez 
Mark Conklin - Free Mark Health
Mike Baldzicki - NASP
 
 

This episode features conversations with
 
Aleeta Postell & Sabeen Hasnie - Walmart Specialty Pharmacy
Amanda Awe PharmD - VPL
Cecelia Byers - Surescripts
Chris Antypas, PharmD
Dan Brooks - Brooks Group
Jeffrey Baird

During this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, sits down with Dr. Paige Kilian, Chief Medical Officer (CMO) for Inovalon, to discuss the outsized role administrative burden is playing in driving primary care physicians and pharmacists out of the patient communities that need them, what we need to do to fix it, and what is possible once we do.

Success in launching new therapies for rare diseases (RDs) implies the ability for the manufacturer to achieve a level of reimbursed price and a level of market access that are commercially viable on the market. Access to RD therapies is challenging because the legal and policy frameworks may be absent, funding may be insufficient and/or payers do not see the justification with the prices for these therapies. The industry has, however, a real opportunity to partner with healthcare stakeholders.  There needs to be continued support to provide the education towards payers, drive evidence-based pricing, and innovative contracting, and address the multiple hurdles of access for these unique therapies. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data on these new therapies?  That is why all stakeholders need to address early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision.
           
Podcast Participants: Jim Clement – Partner & Board Member at Coeus Holdings
                                       Donovan Quill – Executive Vice President at Terebellum

Continuing advances in cell and gene therapy (CGT) are transforming the pharmacy and point of care ecosystem. Recent launches of new CGTs have yielded mixed results on getting the right therapy to the right patients.  The CGTs pipeline and approvals are likely to rise dramatically in the near future. In 2024 alone, up to 21 cell therapy launches and as many as 31 gene therapy launches are on the horizon. Therefore, the launch readiness for these products should be effective so that the therapies can benefit as many patients as possible while ensuring a sufficient return on manufacturers’ investments. With so many new CGTs poised for commercialization, it’s imperative to consider innovative ways for a product launch that benefits CGTs patients. Ensuring that the market, the product, and the company itself are fully prepared for an effective launch will enable success.
 
Podcast Participants: Michelle Rice, CEO, Michelle Rice & Associates
Kenneth Mankowski, DO, FACN, MS Neurologist Specialist, CNS & MS InstituteHost: 
Michael Baldzicki
 

During this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, sits down with Tim McLeroy, Executive Director of Marketing & Patient Services at Noble. They discuss challenges patients face when beginning therapeutic treatment, solutions to provide the training and support that patients need, the impacts of biosimilars and telehealth on patient experience, and cost-effective approaches for patient training and onboarding.Sheila Arquette, RPh, President & CEO of NASP; Tim McLeroy, Executive Director of Marketing & Patient Services at Noble

Rare diseases affect nearly 10% of the US population and transformative changes to research and development, as well as modernized regulatory pathways, have accelerated the entry of orphan drugs to the market. This uptick has necessitated discussions on how best to manage these conditions to ensure the right therapy is provided to the right patient at the right time. This episode is a first step in creating an open and transparent dialogue on the challenges faced by insurers in a resource constrained healthcare environment. As the focus will offer listeners a view of the latest trends in rare disease / orphan drug market access, assessing current payer perspectives, and offering insights and potential implications of the management of rare disease and orphan drugs. By highlighting the key issues and opportunities, we hope that payers, providers, patients, and biopharmaceutical manufacturers will bridge the access gaps and ensure patients can receive medically necessary therapies to ultimately improve patient outcomes.